Literature DB >> 12450693

Comparative evaluation of a combined DTP-HB vaccine in the EPI in Chiangrai Province, Thailand.

Supamit Chunsuttiwat1, Beverley Ann Biggs, James E Maynard, Piyanit Thammapormpilas, Monthakarn O-Prasertsawat.   

Abstract

Combined vaccines have been advocated as an efficient method of paediatric vaccine delivery. This study examined the performance and cost implications for the use of combined DTP-HB vaccine in the Thai immunisation program. Separate DTP and HB and then combined DTP-HB vaccines were used in the infant immunisation program in Chiangrai Province during a 4-year period. DTP vaccination coverage was maintained with the combined vaccine and HB coverage was improved (95.7% for DTP-HB1, 95.2% for DTP-HB2 and 93.8% for DTP-HB3). Seroconversion rates for anti-HBs rose from a baseline of 88.4 to 94.8% with use of the combined vaccine. Seroconversion rates for anti-D (97.5%) and anti-P (89.6%) were higher in the separate vaccine regimen. Although this study was not able to demonstrate that DTP-HB vaccine was more cost saving than the vaccines given separately as baseline vaccine coverage was already high, in settings where coverage rates are much lower the increased cost of combined vaccines may be more justifiable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450693     DOI: 10.1016/s0264-410x(02)00461-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Replacing the measles ten-dose vaccine presentation with the single-dose presentation in Thailand.

Authors:  Bruce Y Lee; Tina-Marie Assi; Korngamon Rookkapan; Diana L Connor; Jayant Rajgopal; Vorasith Sornsrivichai; Shawn T Brown; Joel S Welling; Bryan A Norman; Sheng-I Chen; Rachel R Bailey; Ann E Wiringa; Angela R Wateska; Anirban Jana; Willem G Van Panhuis; Donald S Burke
Journal:  Vaccine       Date:  2011-03-23       Impact factor: 3.641

2.  The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.

Authors:  Sukanta Chatterjee; Sylvan J Rego; Fulton D'Souza; B D Bhatia; Alix Collard; Sanjoy K Datta; Jeanne-Marie Jacquet
Journal:  BMC Infect Dis       Date:  2010-10-15       Impact factor: 3.090

3.  What criteria do decision makers in Thailand use to set priorities for vaccine introduction?

Authors:  Siriporn Pooripussarakul; Arthorn Riewpaiboon; David Bishai; Charung Muangchana; Sripen Tantivess
Journal:  BMC Public Health       Date:  2016-08-02       Impact factor: 3.295

4.  Implementation of hepatitis B vaccine in high-risk young adults with waning immunity.

Authors:  Nawarat Posuwan; Arnond Vorayingyong; Vorapol Jaroonvanichkul; Rujipat Wasitthankasem; Nasamon Wanlapakorn; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PLoS One       Date:  2018-08-20       Impact factor: 3.240

5.  The Success of a Universal Hepatitis B Immunization Program as Part of Thailand's EPI after 22 Years' Implementation.

Authors:  Nawarat Posuwan; Nasamon Wanlapakorn; Pattaratida Sa-Nguanmoo; Rujipat Wasitthankasem; Preeyaporn Vichaiwattana; Sirapa Klinfueng; Viboonsak Vuthitanachot; Siriporn Sae-Lao; Monthana Foonoi; Apinya Fakthongyoo; Jamorn Makaroon; Klaita Srisingh; Duangporn Asawarachun; Somchai Owatanapanich; Norra Wutthiratkowit; Kraisorn Tohtubtiang; Pornsak Yoocharoen; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.